Brought to you by 
Ariel gets two neurological candidates from BTG
19 Dec 2011
Executive Summary
Acute care drug company BTG PLC’s affiliate BTG International Ltd. has licensed spec pharma Ariel Pharmaceuticals Inc. rights to its Phase I acute migraine compound AP1531 and Phase II cognitive decline treatment AP1101.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ariel gets two neurological candidates from BTG
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice